{"id":"NCT01808144","sponsor":"Ardea Biosciences, Inc.","briefTitle":"Lesinurad and Febuxostat Combination Extension Study in Gout","officialTitle":"A Long-Term Extension Study of Lesinurad in Combination With Febuxostat for Subjects With Gout Completing an Efficacy and Safety Study of Lesinurad and Febuxostat","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-03-01","primaryCompletion":"2016-08-09","completion":"2016-10-06","firstPosted":"2013-03-11","resultsPosted":"2018-01-30","lastUpdate":"2018-01-30"},"enrollment":196,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Gout"],"interventions":[{"type":"DRUG","name":"lesinurad","otherNames":[]},{"type":"DRUG","name":"lesinurad","otherNames":[]},{"type":"DRUG","name":"febuxostat","otherNames":[]}],"arms":[{"label":"lesinurad 400 mg + febuxostat 80 mg","type":"EXPERIMENTAL"},{"label":"lesinurad 200 mg + febuxostat 80 mg","type":"EXPERIMENTAL"}],"summary":"This study will assess the serum uric acid lowering effects and safety of lesinurad in combination with febuxostat over a long-term timeframe.","primaryOutcome":{"measure":"Percentage of Participants With an sUA Level That is < 5.0 mg/dL","timeFrame":"Up to approximately 2.5 years (at Extension Month 12)","effectByArm":[{"arm":"Lesinurad 400 mg + Febuxostat 80 mg","deltaMin":82.5,"sd":null},{"arm":"Lesinurad 200 mg + Febuxostat 80 mg","deltaMin":77.8,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":3,"exclusionCount":1},"locations":{"siteCount":72,"countries":["United States","Australia","Canada","New Zealand","Poland","Switzerland"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":16,"n":97},"commonTop":["Blood creatinine increased","Nasopharyngitis","Hypertension","Bronchitis","Upper respiratory tract infection"]}}